BillionToOne, Inc. Class A Common Stock

BLLN · Moat type: UNBESTIMMT

MoatScore

2/10

Fair Value

n/a

Margin of Safety

n/a

Rating

MEIDEN

GESCHÄFTSMODELL BillionToOne (BLLN) develops and markets molecular diagnostic tests – particularly prenatal genetic tests (NIPS/NIPT) as well as oncological liquid biopsies – and generates revenues primarily through laboratory testing fees that are reimbursed by health insurance companies, hospitals, and directly by patients.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.